Nelson Gomez, MD
Critical Care Medicine · Brandon, FLNPI 1013949544
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $148,175 of the $179,717 with a category attached, or 82.4%. GSK accounts for 87.5% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2023 at $82,582 and has fallen 93.4% since, to $5,449 in 2025. Among critical care medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 449 payments — averaging $400.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$157K
- Intuitive Surgical$17K
- AstraZeneca$1K
- Boehringer Ingelheim$494
- Takeda Pharmaceuticals U.S.A., Inc.$338
- Amgen$335
- plus $3K from 31 others
What the payments were for
- Speaking & faculty fees$148,17582%
- Travel & lodging$4,9083%
- Food & beverage$10,0486%
- Education$16,5859%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 220 | $157,245 |
| Intuitive Surgical | 15 | $17,257 |
| AstraZeneca | 58 | $1,236 |
| Boehringer Ingelheim | 21 | $494 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $338 |
| Amgen | 16 | $335 |
| Insmed, Inc. | 12 | $314 |
| Regeneron Healthcare Solutions, Inc. | 9 | $265 |
| Inspire Medical Systems, Inc. | 3 | $252 |
| Sanofi | 8 | $217 |
| Mallinckrodt Hospital Products Inc. | 6 | $163 |
| Mylan Specialty L.p. | 6 | $159 |
| United Therapeutics Corporation | 7 | $157 |
| Actelion Pharmaceuticals US, Inc. | 6 | $138 |
| Baxter Healthcare | 6 | $136 |
| Grifols USA, LLC | 5 | $131 |
| ANI Pharmaceuticals, Inc. | 4 | $130 |
| Harmony Biosciences LLC | 4 | $105 |
| Axsome Therapeutics, Inc. | 3 | $85 |
| Olympus America Inc. | 2 | $82 |
| Philips North America LLC | 3 | $79 |
| Verona Pharma, Inc. | 2 | $52 |
| Teva Pharmaceuticals USA, Inc. | 1 | $49 |
| Inogen, Inc. | 4 | $46 |
| AbbVie | 1 | $26 |
| Vapotherm Inc | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $23 |
| 3b Medical, Inc. | 1 | $21 |
| Phadia US Inc. | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Electromed, Inc. | 1 | $18 |
| Pharming Healthcare, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Merck | 1 | $17 |
| Viatris Specialty LLC | 1 | $14 |
| Penumbra, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$47,988
- AREXVY$40,474
- Da Vinci Surgical System$13,974
- ANORO ELLIPTA$12,843
- ION$3,000
- Inspire$153
- BREZTRI$125
How this compares
$179,717 in reported general payments places this provider in the 95th percentile of 618 critical care medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 608 | $755,681 |
| OfevNintedanib Esylate | 12 | $154,287 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $135,025 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 89 | $111,377 |
| Breo ElliptaFluticasone/Vilanterol | 127 | $81,390 |
| NucalaMepolizumab | 12 | $51,403 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 44 | $50,253 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $23,562 |
| Spiriva RespimatTiotropium Bromide | 18 | $22,321 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 206 | $7,534 |
| Wixela InhubFluticasone Propion/Salmeterol | 26 | $7,146 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $6,641 |
| Azelastine Hcl | 177 | $6,635 |
| Arnuity ElliptaFluticasone Furoate | 12 | $4,955 |
| Montelukast Sodium | 254 | $3,130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Arnuity Ellipta | $157,245 | $1,004,807848 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $494 | $200,17050 claims |
| Grifols USA, LLCProlastin C | $131 | $135,02512 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,236 | $56,89457 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 618 critical care medicine providers in Florida.
Other critical care medicine in Brandon
- Louis GuzziOrlando$635K
- Fortune AlabiKissimmee$587K
- Debabrata BandyopadhyayTampa$398K
- Fred UmehKissimmee$371K
- Amit TandonWesley Chapel$338K
- Omid ZadOrlando$325K
- Eddy GutierrezJacksonville$315K
- Maximo LamaKissimmee$255K
- William CroleyPensacola$211K
- Vinny SamuelSt Petersburg$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.